Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2010 March 1; 120(3): 668–680.
Published online 2010 February 8. doi:  10.1172/JCI36667
PMCID: PMC2827943

CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis


Ewing sarcoma (EWS) is an aggressive bone tumor of uncertain cellular origin. CD99 is a membrane protein that is expressed in most cases of EWS, although its function in the disease is unknown. Here we have shown that endogenous CD99 expression modulates EWS tumor differentiation and malignancy. We determined that knocking down CD99 expression in human EWS cell lines reduced their ability to form tumors and bone metastases when xenografted into immunodeficient mice and diminished their tumorigenic characteristics in vitro. Further, reduction of CD99 expression resulted in neurite outgrowth and increased expression of β-III tubulin and markers of neural differentiation. Analysis of a panel of human EWS cells revealed an inverse correlation between CD99 and H-neurofilament expression, as well as an inverse correlation between neural differentiation and oncogenic transformation. As knockdown of CD99 also led to an increase in phosphorylation of ERK1/2, we suggest that the CD99-mediated prevention of neural differentiation of EWS occurs through MAPK pathway modulation. Together, these data indicate a new role for CD99 in preventing neural differentiation of EWS cells and suggest that blockade of CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS.


Ewing sarcoma (EWS) is the second most common bone tumor of children and young adults (1). These tumors are very aggressive and require either surgery and/or radiation therapy for control of the primary tumor site, along with intensive chemotherapy to treat micrometastatic deposits. These treatments are associated with significant short- and long-term side effects. New therapeutic approaches are likely to come from an improved understanding of the molecular basis of this tumor.

EWSs have a “small round blue cell tumor” histologic phenotype that is characterized by predominantly undifferentiated sheets of cells with relatively little stroma (1). This lack of differentiation has led to difficulty in understanding the tumor cell of origin. In some cases, however, EWSs have evidence of limited neural differentiation, including Homer-Wright rosettes, neural processes, neurosecretory granules, and neural immunohistochemical markers (26). This phenotype has suggested that EWSs may arise from the neural crest. Recently, a number of investigators have suggested that the tumor has a mesenchymal stem cell origin (711).

EWS is characterized by the presence of recurrent chromosomal translocations that fuse the EWSR1 gene (encoding the EWS protein) on chromosome 22 with various ETS genes (12). The most common fusion, EWS/FLI, is present in 85% of cases, with other fusions accounting for the remaining cases (13). In each case, the DNA-binding domain of the ETS factor and a transcriptional activation domain contributed by EWS are retained, supporting experimental data suggesting that EWS/FLI functions as an aberrant transcription factor (14, 15).

The effects of EWS/FLI expression are strongly dependent on cellular background (reviewed in ref. 16). For example, EWS/FLI transforms immortalized murine NIH3T3 fibroblasts and is required for the oncogenic phenotype of patient-derived EWS cells (14, 17). Conversely, introduction of EWS/FLI into primary human or murine fibroblasts leads to growth arrest or cell death, respectively (18, 19). In other contexts, EWS/FLI expression induces transdifferentiation and thus induces cells to exhibit a neural phenotype (2022). These data suggest that oncogenic transformation by EWS/FLI requires a permissive cellular background. The critical factors in the permissive background are largely unknown but may include disruption of the p53 and RB pathways and the presence of an intact IGF pathway (18, 19, 23). Furthermore, these studies suggest that EWS/FLI itself may induce the neural phenotype of EWS, rather than the phenotype resulting from the cell of origin of the tumor.

While assays for EWS/FLI expression are becoming widely used as a molecular diagnostic approach for EWS, the most commonly used diagnostic marker is CD99 (1). CD99 (also known as MIC2, and recognized by antibodies 12E7, HBA71, and O13) is a 32-kDa integral membrane glycoprotein that is highly expressed in most cases of EWS (24). CD99 has a key role in several biological processes, including cell adhesion, migration, and apoptosis; differentiation of T cells and thymocytes; diapedesis of lymphocytes to inflamed vascular endothelium; maintenance of cellular morphology; and regulation of intracellular membrane protein trafficking (2530). While the expression of CD99 is high in EWS, and in some cases of rhabdomyosarcoma, mesenchymal chondrosarcoma, and T-lineage leukemias and lymphomas, in other tumors, such as osteosarcoma and Hodgkin lymphoma, CD99 is expressed at low levels and may function as a tumor suppressor (24, 3138).

In EWS, engagement of CD99 with antibodies results in apoptosis and enhances sensitivity to chemotherapeutic agents (39, 40). However, the normal function of CD99 in EWS is unknown. In this study, we found that CD99 is required for EWS transformation. Reduction of CD99 expression in patient-derived EWS cells abrogated oncogenic transformation and induced cells toward a neural differentiation phenotype. Interestingly, we found that CD99 is normally expressed on the surface of human mesenchymal stem cells, which have been recently suggested to be the EWS cell of origin, indicating that CD99 is a key component of the cellular context that allows ongoing EWS/FLI expression without growth arrest or cell death. Furthermore, gene expression profiling studies identified a CD99 signature that contributed to previously reported EWS/FLI signatures and supported the hypothesis that CD99 affects differentiation and malignancy of EWS cells. These data define a new role for CD99 as an inhibitor of neuronal differentiation and suggest that blockade of basal CD99 function may be a new therapeutic approach for EWS.


CD99 contributes to cell proliferation, migration, and metastasis of EWS cells and inhibits their neural differentiation.

To define the role of CD99 expression in EWS, we took a loss-of-function approach. Plasmids expressing either an shRNA targeting the 3ι untranslated region (UTR) of CD99 (called CD99-shRNA) or a scrambled shRNA control (CTR-shRNA) were used to generate stable transfectants of TC-71 and IOR/BRZ patient-derived EWS cell lines. Efficient knockdown of CD99 was confirmed at the RNA level (data not shown) and at the protein level using Western blot analysis and flow cytometry (Figure (Figure1,1, A and B). In addition, to verify that the biological effects were dependent on diminished CD99 expression, and to exclude off-target or other nonspecific effects, we performed “knockdown/rescue” experiments. TC-71 and IOR/BRZ cells expressing the CD99-shRNA construct were transfected with a CD99 cDNA that did not contain the endogenous 3ι UTR and was thus resistant to the RNAi effect (Figure (Figure1C).1C). We found that cells with reduced expression of CD99 showed a concomitant reduction in both monolayer and anchorage-independent growth (Figure (Figure2,2, A and B) and reduced cell motility (Figure (Figure2C).2C). Additionally, these cells demonstrated an increase in adhesion to extracellular matrix components, including collagen I and IV (Figure (Figure2D).2D). The magnitude of the effects correlated with the level of CD99, with TC-71 exhibiting the strongest effects and IOR/BRZ showing a more modest effect. The reexpression of CD99 in silenced clones (Figure (Figure1C)1C) completely rescued growth and migratory capacities to the same level as in the parental cell lines (Figure (Figure2,2, A–C). Nearly identical results were obtained using 3 additional siRNA constructs in a transient transfection assay, in which EWS cells demonstrated reduced cell motility and increased cell adhesion to collagen I and IV (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI36667DS1). These effects were not simply due to global changes in cellular membrane protein content, as the expression levels of integrins β1 and αVβ3 and several growth factor receptors were unchanged in response to CD99 knockdown (data not shown).

Figure 1
Silencing of CD99 by shRNA plasmid.
Figure 2
In vitro growth features of EWS cells silenced for CD99.

To determine the effects of CD99 knockdown in vivo, we performed mouse xenograft experiments (Table (Table1).1). Reduction of CD99 expression in either TC-71 or IOR/BRZ EWS cells with the CD99-shRNA construct resulted in a reduction in local tumor growth, as measured by an increased time to tumor development and a reduction in tumor size. Furthermore, the development of bone metastasis was also significantly reduced. Both tumorigenicity and metastasis ability of EWS cells were regained when CD99 was reexpressed. Taken together, these data demonstrate that ongoing CD99 expression is required for the oncogenic phenotype of EWS cells in vitro and in vivo.

Table 1
Tumorigenicity and metastasis of CD99-silenced cells

The cell growth inhibition induced by CD99 knockdown was due to a block at the G2/M phase of cell cycle (Figure (Figure3A)3A) and increased apoptosis (Figure (Figure3B).3B). In fact, the analysis of some cell cycle regulators and apoptosis mediators indicated an upregulation of p21 or p27, two molecular effectors that participate in the G1 and G2 checkpoints causing cell arrest (41), as well as a downregulation of the antiapoptotic protein Bcl-2 in cells deprived of CD99 (Figure (Figure3C).3C). No differences were observed with respect to expression of cyclins and cyclin-dependent kinases (CDKs). However, this was expected, since most of these genes are downstream targets of EWS/FLI, which is present on the CD99-knockdown cells (data not shown). Upregulation of p21 or p27 is reported to be sufficient to compensate cyclin D1 activity, thus allowing cell arrest (42). Increased expression of p21 is independent of p53 activity in these cells, since both the 2 parental cell lines (TC-71 and IOR/BRZ) have truncated and inactive forms of p53 (data not shown). In addition, the increased expression of p21 and p27 in CD99-deprived cells was observed despite the presence of EWS/FLI, which was reported to attenuate p21 and/or p27 expression levels (41, 43, 44), and may be due to inhibition of PI3K/Akt pathway (Figure (Figure3C),3C), which is known to negatively regulate these 2 cell cycle inhibitors (45).

Figure 3
CD99 influences cell proliferation and apoptosis of EWS cells.

Not only are both p21 and p27 necessary to restrain cell cycle progression, but they may also exert positive or negative effects on apoptosis, cell movement, and differentiation (41) through a complex and still not entirely understood network of molecular mechanisms. Here we found that introduction of the CD99-shRNA construct induced a phenotype consistent with neural differentiation. Reduction of CD99 expression resulted in neurite outgrowth and increased expression of β-III tubulin and H-neurofilament (H-NF), a late and very specific marker of neuronal differentiation (711, 46) (Figure (Figure4,4, A and B). Neurofilaments are composed of 3 groups of microheterogeneous subunits with molecular masses of 65 kDa (L-NF), 160 kDa (M-NF), and 200 kDa (H-NF). L-NF and M-NF are expressed at early stages of neuronal development, while H-NF is expressed later in the terminal phase. Exposure of cells to nerve growth factor (NGF; 20 ng/ml) or low-serum medium (1% Iscove’s modified Dulbecco’s medium [IMDM]) for 72 hours induced high expression of H-NF in cells with reduced expression of CD99 but not in parental cells (Figure (Figure4C),4C), further sustaining the association between CD99 expression and neural differentiation. Quantitative analysis of neurite outgrowth showed modulation of neuritis number according to the expression of CD99. A significant increase in cells with long cytoplasmic extensions was observed in cells silenced for CD99 (40 of 282, 14% in TC-71 vs. 123 of 290, 42% in TC-CD99-shRNA#1; P < 0.001, χ2 test). Reexpression of CD99 reversed the morphologic changes (number of neurites: 50 of 294, 17% in TC-CD99-shRNA#1-CD99 cells) and expression of H-NF or β-III tubulin back to baseline, again demonstrating that this was not due to off-target or other nonspecific effects (Figure (Figure4A).4A). A similar trend was observed for IOR/BRZ cells: the percentage of cells that stained for H-NF increased from 32% in control to 90% in BRZ-CD99-shRNA#1 cells. Transient downregulation of p21 in TC-CD99-shRNA#2 cells was associated with a decrease in H-NF expression (Figure (Figure4B),4B), thus indicating in p21 one possible functional connector between CD99-induced cell cycle inhibition and neural differentiation. Indeed, in specific cellular systems, p21 has been reported to have a role in the process of commitment to terminal differentiation (47). To assess the relationship among CD99 expression, transformation, and neural differentiation more broadly in EWS, we analyzed a panel of patient-derived EWS cells for CD99 and H-NF expression (Table (Table2).2). We found an inverse correlation between CD99 and H-NF expression (Pearson correlation test, r = –0.93; P = 0.0003) and a positive association between CD99 and oncogenic transformation (Pearson correlation test, r = 0.85; P = 0.005 with respect to soft agar). There was also an inverse correlation between neural differentiation (as measured by H-NF expression) and oncogenic transformation in vitro and in vivo (Pearson correlation test, r = –0.82; P = 0.04, with respect to soft agar growth). A further confirmation comes from the EWS cell line 6647. By continuous exposure of 6647 cells to the anti-CD99 mAb 0662 (40), we obtained a cell variant with stable downregulation of CD99 (Table (Table2).2). This cell variant, here named 6647/CD99low, displayed significantly increased expression of H-NF (P = 0.03, Student’s t test) and reduced soft agar growth (P = 0.001, Student’s t test). These data suggest that CD99 contributes to oncogenic transformation by preventing terminal neural differentiation of EWS cells.

Figure 4
CD99 influences neural differentiation in EWS and human MSCs.
Table 2
Relationship among level of CD99 expression, neural differentiation, and malignancy in a panel of EWS cell lines

To determine whether these results were specific to EWS cells or were more generalized, we analyzed the relationship between CD99 and neural differentiation in human mesenchymal stem cells (MSCs). MSCs have recently been proposed to be the cell of origin of EWS (711). We first confirmed that our preparation of human bone marrow–derived MSCs expressed cell surface markers that have been previously reported for this cell type, including CD166, CD105, and CD29 (4850) (Supplemental Figure 2A). As expected, these cells did not express the hematopoietic markers CD45 and CD34. We found that MSCs expressed CD99 at levels comparable to those found on patient-derived 6647 EWS cells. Seven additional independent preparations of MSCs demonstrated moderate to high levels of CD99 expression (data not shown). These data suggest that the putative EWS cell of origin has an appropriate cellular background to tolerate EWS/FLI expression without undergoing terminal differentiation.

We next assessed the levels of CD99 under differentiating conditions. MSCs can be induced to differentiate toward various lineages, including osteocytes, chondrocytes, and adipocytes (49, 50). MSCs can also be induced to differentiate toward a neural phenotype under specific conditions (51, 52). We found that under osteoblastic differentiating conditions, MSCs retained basal levels of CD99 protein expression (Supplemental Figure 2B). However, CD99 expression was significantly reduced when MSCs were induced to undergo neural differentiation (Figure (Figure4E).4E). These data suggest that neural differentiation cannot proceed without downregulation of CD99 levels.

We also confirmed a functional role for CD99 in a recently described murine model of EWS (53, 54). Because there is no well-defined CD99 allele in the mouse genome (54), this system allows for an analysis of CD99 activity in the absence of endogenous CD99 expression. The C3H10T1/2 murine mesenchymal multipotent cell line loses its ability to differentiate down osteoblastic and adipocytic lineages following EWS/FLI transfection but instead acquires a neural phenotype and tumorigenic properties (53).

Introduction of the CD99 cDNA into this model system (Figure (Figure5A)5A) repressed features of neural differentiation, as shown by reduced expression of β-III tubulin and H-NF (Figure (Figure5B).5B). Furthermore, CD99 expression increased both cell motility (Figure (Figure5C)5C) and soft agar colony formation (Figure (Figure5D).5D). In vivo, CD99 expression increased tumor growth. The C3H10T1/2-CD99 cells gave rise to tumors in all of the animals, compared with 50% of mice when the parental cells were injected, and the tumor growth rate was significantly increased (Figure (Figure5E).5E). Taken together, these data suggest that CD99 blocks neural differentiation in multiple cell types and contributes to the oncogenic phenotype of EWS.

Figure 5
Analysis of CD99 activity in the absence of endogenous CD99 expression.

Expression profiling of CD99 in EWS identifies MAPK pathway modulation.

To determine the molecular basis for CD99 function in EWS, we analyzed the gene expression profile of EWS cells expressing the CD99-shRNA construct and compared it with that of cells expressing a control construct using Agilent G4110B oligonucleotide microarrays. We identified the pathways differentially expressed in CD99-shRNA cells with respect to control by a functional class scoring analysis (see Supplemental Methods) applied to gene lists selected in a blinded manner on TC-71 and IOR/BRZ cells (Supplemental Table 1). Analysis of the most silenced TC-71 cells confirmed the role of CD99 on differentiation and transformation. Analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations identified a number of pathways that were significantly modulated by CD99 (P < 0.05) (Table (Table3).3). The most differentially regulated pathway was neuroactive ligand receptor interaction. The hedgehog signaling pathway, which is associated with neuronal differentiation in the central nervous system, was also modulated, as were pathways involved in oncogenic transformation, such as adhesion, metabolism, and signaling. Clustering analysis also indicated that among the 30 most deregulated genes (P < 0.05, log ratio >2 or <0.5), 19 (63%) are expressed in and/or functionally connected with nervous system development (listed in bold in Supplemental Figure 3A; Supplemental Table 2). To gain new insights into functional mechanisms underlying the CD99-mediated phenotype, we considered together the genetic profiles of TC-71 and IOR/BRZ cells (Supplemental Table 3). KEGG and BioCarta pathway analysis revealed that the expression level of genes involved in the MAPK pathway are significantly altered in CD99-silenced cells (Supplemental Figure 3B). This was of interest because the MAPK pathway is known to be involved in neuronal development and differentiation (5559). Furthermore, while transient activation of the MAPK pathway induces cellular proliferation of PC12 cells, prolonged activation promotes neural differentiation of these cells (60). We therefore asked whether the MAPK pathway might be involved in the neural differentiation blockade mediated by CD99. We observed an increase in ERK1/2 activation in CD99-silenced cells by cytofluorometric analysis (Figure (Figure6A),6A), ELISA cell-based tests (Figure (Figure6B),6B), and Western blotting (Figure (Figure6C).6C). Confocal microscopy confirmed that knockdown of CD99 led to an increase in levels of phosphorylated ERK1/2 (Figure (Figure6D),6D), which was particularly evident in the nucleus (Supplemental Figure 3C), whereas total ERK1/2 protein was distributed uniformly throughout the cytoplasm and nucleus. We next used the ERK inhibitor PD98059 to determine the functional consequences of MAPK pathway activity (Supplemental Figure 3D). In parental TC-71 cells, PD98059 treatment resulted in diminished proliferation (Figure (Figure6E),6E), as expected. In TC-71 cells containing the CD99-shRNA construct, however, PD98059 did not prevent the observed growth inhibition but prevented the neural differentiation induced by CD99 knockdown (Figure (Figure6,6, E and F). Both H-NF and β-III tubulin staining were in fact reversed by 48-hour treatment with PD98059. These effects were reversed when expression of CD99 was regained (data not shown). These data suggest that CD99 prevents neural differentiation of EWS via a MAPK-dependent pathway.

Figure 6
Insights into the mechanisms of CD99-silenced cells.
Table 3
Significant variations in TC-CD99-shRNA cells compared with controls for KEGG pathways according to the gene set comparison toolA

CD99 and EWS/FLI interact in sustaining the EWS phenotype.

Both EWS/FLI and CD99 are required for the oncogenic phenotype of EWS. We first considered the epistatic relationship between EWS/FLI and CD99 using gene expression profiling data. We reasoned that if one protein alters the expression of the other, then there will be significant similarities in their gene expression profiles. We used the CD99 signature that included 106 genes (76 upregulated and 30 downregulated in both TC-71 and IOR/BRZ CD99-silenced cells; Figure Figure7A7A and Supplemental Table 3) and compared that with Affymetrix microarray platform gene expression data for EWS/FLI generated by RNAi experiments in SK-N-MC and EW-24 cells (10) and in EWS502 and TC-71 cells (61). Genes were mapped to their UniGene identifiers to allow for comparison across different microarray platforms. The EWS/FLI knockdown datasets were first limited to those genes that represent the CD99 expression signature and subsequently used to perform Spearman correlation tests (P = 0.02, r = 0.23), principal component analysis (PCA) (Figure (Figure7B),7B), and hierarchical clustering (Supplemental Figure 4A). Using these approaches, we found that the CD99 signature allowed for a clear separation of EWS/FLI knockdown cells from controls, suggesting that the CD99 signature overlaps with the EWS/FLI signature.

Figure 7
Relationship of CD99 expression and EWS/FLI expression.

Previous studies have suggested that EWS/FLI induces a neural phenotype in a variety of cellular contexts (2022). Interestingly, in some studies, EWS/FLI also induces CD99 expression (18, 20, 62). While regulation of CD99 by EWS/FLI was not reported in EWS cells that were treated with RNAi against the fusion protein (17, 63), inspection of the raw data from one of these studies (17) demonstrated that knockdown of EWS/FLI resulted in a modest decrease in CD99 expression (data not shown). Here we provide evidence that CD99 is a putative target of EWS/FLI1. A ChIP assay was performed in TC71 and IOR/BRZ EWS cell lines, and we found that EWS/FLI1 was associated to CD99 promoter (Figure (Figure7C).7C). Taken together, these data suggest that CD99 is regulated by EWS/FLI and thus contributes to the oncogenic phenotype mediated by the fusion.


EWS has served as a paradigm for translocation-associated tumors because it is highly associated with the expression of the EWS/FLI (and other EWS/ETS) translocation oncoproteins. In this regard, it has been thought that understanding the function of EWS/FLI would be the key to understanding the process of oncogenesis for this unusual tumor, which may then provide a new understanding for oncogenic pathways in general. It has become clear in recent years, however, that EWS/FLI is not the whole story in EWS and that studying both downstream and parallel pathways will be required for a full comprehension of oncogenesis in this tumor.

Cell surface expression of CD99 is a very consistent feature of EWS (24, 31, 34). Indeed, CD99 is currently considered to be one of the best diagnostic immunohistochemical markers for this disease (1). In this report, we demonstrate that CD99 expression is critical for the oncogenic phenotype of EWS. We provide evidence that modulations in the expression levels of CD99 significantly modify cell growth in anchorage-independent conditions and also cell migration, tumorigenesis, and metastasis ability. CD99 participates in the transformed phenotype by serving to prevent terminal differentiation of EWS cells toward a neural phenotype. This effect is important because EWS/FLI itself appears to drive cells toward a neurally differentiated fate.

The cell of origin of EWS remains uncertain, but emerging evidence suggests that it arises from an MSC. For example, RNAi-mediated silencing of EWS/FLI in EWS cells allows those cells to exhibit a gene expression pattern that is similar to that of MSCs (10). Furthermore, silencing of EWS/FLI allows EWS cells to be differentiated toward adipocytic, chondrocytic, and osteocytic lineages (10). Conversely, introduction of EWS/FLI into murine MSCs blocked their ability to differentiate into osteocytic or adipocytic lineages, induced markers of neural differentiation, and resulted in oncogenic transformation (9, 11). Introduction of EWS/FLI into human MSCs induced a gene expression pattern that was similar to that of EWS cells (including the expression of NKX2.2, a neural marker that is critical for EWS oncogenesis; ref. 17) and caused them to adopt a more invasive phenotype in a Matrigel invasion assay (8).

Introduction of EWS/FLI into other nontransformed cell types results in growth arrest (reviewed in ref. 16). Our observation that human MSCs express CD99 at baseline suggests a mechanism by which MSCs serve as a permissive cellular environment for EWS/FLI expression. We propose that EWS/FLI induces cells to undergo neural differentiation but that the basal and possibly inducible expression of CD99 prevents terminal differentiation. The net result of these balancing effects is a cell that exhibits some features of the neural phenotype but maintains its growth capacity. Subsequent activation or repression of other molecular pathways would then be required for these cells to express the full oncogenic phenotype of EWS.

Previous studies showed that CD99 was capable of eliciting modulation of several intracellular pathways, including PI3K/Akt and RAS/MAPK (64, 65) We found that CD99 knockdown inhibited Akt while increasing ERK1/2 phosphorylation. The effects on PI3K/Akt may explain the blockade of CD99-silenced cells in G2/M cell cycle phase and their increased expression of the growth inhibitors p21 and/or p27, since this pathway has been shown to be required for G2/M phase progression and to play a key role in the stabilization of p21 and p27 (45). The lack of p27 degradation can be sufficient to stop RAS-induced proliferation (55). In addition, in normal primary cells, the RAS pathway may contribute to induction of p53-independent p21 upregulation (55), thus contributing to cell growth inhibition. In CD99-deprived cells, however, we found that the major role of RAS/MAPK pathway is related to regulation of differentiation. Activation of the RAS/MAPK pathway is well known to be involved in neural differentiation and survival (5659, 66). This may be related to signal duration, as experiments in PC12 pheochromocytoma cells demonstrated that transient activation of the pathway resulted in cellular proliferation, whereas prolonged pathway activation resulted in neural differentiation (60). In particular, prolonged nuclear ERK1/2 phosphorylation seems to be crucial for shifting the biological functions of ERK1/2 toward neural development and differentiation. It has previously been shown that EWS/FLI activates the RAS/MAPK signaling pathway in immortalized murine fibroblasts (67). Our findings demonstrate that CD99 inhibits the activation of ERK1/2. This suggests a model according to which EWS/FLI activates, and CD99 represses, the MAPK pathway and together they serve to fine-tune levels of pathway activation that allow for proliferation but prevent terminal neural differentiation. We demonstrate that the mechanism behind the block in transformation mediated by CD99 relies on inhibition of RAS signaling. This is surprising, because most tumors are thought to rely on increased RAS activity for their proliferative capacity. However, in some primary vertebrate cells, including neuronal, adipocytic, and myeloid cells, RAS induces differentiation, in some cases accompanied by growth arrest (55). Sustained activation of ERK1/2 accelerated neurite outgrowth and concomitantly increased transcriptional activation of genes involved in the differentiation process, such as p21 (68), expression of which was also found to be enhanced in our neurally driven EWS cells. Thus, our data suggest that unabated RAS signaling may drive a differentiated phenotype under certain circumstances also in tumor cells, challenging the classic paradigm according to which RAS is a primary driver of oncogenic transformation (69). The fine definition of these mechanisms is clearly beyond the purposes of this article. However, the fact that CD99 activates pathways that in the normal context favor cell differentiation may be considered a further confirmation of its importance in the reversal of malignancy of EWS cells.

One question that remains is whether CD99 is a downstream target of EWS/FLI. CHiP analysis in our hands supported the hypothesis that CD99 is a direct target of EWS/FLI. However, the data remain somewhat contradictory. On one hand, introduced expression of EWS/FLI in some model systems, such as human primary fibroblasts, human MSCs, and human rhabdomyosarcomas, induces CD99 expression (8, 18, 20). On the other hand, CD99 expression levels have not been reported to be changed in experiments in which EWS/FLI was knocked down by RNAi in EWS cells (17, 63). In the latter cases, CD99 expression was not monitored explicitly, but rather was only evaluated via microarray. Inspection of the raw microarray data from one of these studies (17) revealed that CD99 expression was modestly reduced following EWS/FLI knockdown in 3 of 4 experiments (S.L. Lessnick, unpublished observations). These observations may be reconciled by our finding that human MSCs express CD99 at baseline. If EWS arises from MSCs, then CD99 may already be expressed at or near a maximal level, and EWS/FLI may provide only a minor contribution to its regulation. In other cell types that do not normally express CD99, the contribution of exogenously introduced EWS/FLI may be more significant. This may then explain our observations of a modest overlap between the EWS/FLI and CD99 gene expression signatures in EWS. Further work is needed to fully evaluate this hypothesis.

In summary, we have shown that CD99 is required for the EWS oncogenic phenotype. CD99 appears to function by blocking a terminally differentiated phenotype that is induced by EWS/FLI, and this process is dependent on changes in MAPK pathway signaling. These data suggest a new therapeutic approach to EWS based on modulating the differentiation of the tumor.


Isolation and differentiation of bone marrow MSCs.

After receipt of informed consent, human primary MSCs were obtained from bone marrow aspirates (iliac crest) of 8 patients undergoing hip replacement surgery and phenotyped as bone marrow MSCs by flow cytometry (negative for CD45 and CD34, positive for CD166, CD105, and CD29; dilution specified in Supplemental Methods). MSC cultures were provided by E. Lucarelli (Rizzoli Institute, Bologna, Italy). Osteoblastic and neural differentiation of MSCs was obtained following procedures described in refs. 70 and 71, respectively.

Cell lines.

EWS cell lines were grown as described previously (40). Murine C3H10T1/2 and C3H10T1/2 cells transfected with EWS/FLI-1 (C3H10T1/2 EF) cell lines were cultured as described (53) and were provided by F. Lecanda (University of Navarra, Pamplona, Spain).


For transient silencing of CD99 and CDKN1A, EWS cells were transfected using Lipofectamine (Invitrogen) following the manufacturer’s protocols. siRNA sequences are provided in Supplemental Methods.

For stable silencing, an shRNA plasmid (pSilencer 2.1-U6 Neo vector; Ambion) expressing CD99 siRNA-1 (5′-GATCCGGCTGGCCATTATTAAGTCTTCAAGAGAGACTTAATAATGGCCAGCCTTTTTGGAAA-3′) was created, and EWS cells were transfected using the calcium phosphate transfection method. Stable transfectants expressing shRNA-CD99 (TC-CD99-shRNA#1 and #2 or BRZ-CD99-shRNA#1 and #2) or negative controls (TC-CTR-shRNA or BRZ-CTR-shRNA) were obtained after selection in neomycin (500 μg/ml) (Sigma-Aldrich). The pcDNA3 CD99 vector, expressing the entire CD99 open reading frame but lacking the 3′ UTR, and pcDNA6/V5-His (Invitrogen), a plasmid that provides blasticidin resistance (5 μg/ml), were cotransfected into TC-CD99-shRNA#1 and BRZ-CD99-shRNA#1 cells using the calcium phosphate transfection method to induce reexpression of CD99. Resistant cellular pools were isolated (TC-CD99-shRNA#1-CD99 and BRZ-CD99-shRNA#1-CD99). C3H10T1/2 EF cells were transfected with the pcDNA3 CD99 vector or with empty vector using the calcium phosphate transfection method. Cellular pools resistant to neomycin (500 μg/ml) were isolated (C3H10T1/2 EF CD99; C3H10T1/2 EF empty).

RNA extraction.

Total RNA was extracted by the TRIzol extraction kit (Invitrogen). Quality and quantity of RNA samples were assessed with NanoDrop analysis (NanoDrop Technologies) and/or with an Agilent 2100 Bioanalyzer (Agilent Technologies).

Biochemical and cellular assays.

Details about Western blotting, cell-based ELISA, monolayer growth assay, motility assay, soft agar assay, ECM adhesion test, cellular morphology study, and apoptosis and cell cycle analysis are provided in Supplemental Methods.

Flow cytometry and immunostaining.

Standard protocols were followed. Procedures are described in detail in Supplemental Methods. Cell cycle analysis was performed by using ModFit software (Verity Software House).

Treatment with PD98059.

Twenty-four hours after cell seeding, medium was replaced by IMDM plus 10% FBS with or without (control) the MEK/MAPK inhibitor PD98059 (50 μM) (Calbiochem). After 48 hours of treatment, cell growth and expression of H-NF were assessed.

Tumorigenicity and metastasis.

Female athymic 4- to 5-week-old Crl:CD-1-nu/nu BR mice (Charles River) were used. Tumorigenicity was assessed after s.c. inoculation of 5 × 106 cells. Metastases were determined by injection of 2 × 106 viable cells in a tail lateral vein. Animals were checked by X-ray for the presence of bone metastases. Experiments were authorized by the institutional review board of the University of Bologna and performed according to Italian and European guidelines.

Microarray analysis.

Experimental models were profiled by using 1A (V2) Oligo Microarray G4110B slides (Agilent Technologies). Microarray data are available at the Gene Expression Omnibus database ( with the accession number GSE10993. A complete description of the microarray analysis is provided as Supplemental Methods. Hierarchical clustering using Pearson correlation and principal component analyses was performed using MeV TM4 software ( The KEGG pathways were analyzed by using a FatiGOPlus program (

BioCarta pathway analysis.

Pathway analysis was performed by using BioCarta:


ChIP analysis was carried out in TC71 and IOR/BRZ cells as described in Supplemental Methods. The negative control promoter primers used for ChIP were previously described (72, 73).


Differences among means were analyzed using 2-tailed Student’s t test. Fisher’s exact test was used for frequency data. Kaplan-Meier and log-rank methods were used, respectively, to draw and evaluate the significance of survival curves in EWS patients. A P value less than 0.05 was considered significant.

Supplementary Material

Supplemental data:
Supplemental Excel file 1:


We thank G. Bernard and A. Bernard of the Faculté de Médecine de Nice, France, for scientific assistance and discussion; and S. Benini and C. Ghinelli for their invaluable technical help. This work was supported by grants from the Italian Association for Cancer Research (K. Scotlandi), the European Project PROTHETS (no. 503036), Eurobonet (no. 018814), the Terri Anna Perine Sarcoma Fund, the Liddy Shriver Sarcoma Initiative, and Huntsman Cancer Institute/Huntsman Cancer Foundation (S.L. Lessnick), and NIH support to the Huntsman Cancer Institute (P30 CA42014).


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2010;120(3):668–680. doi:10.1172/JCI36667.

Anna Rocchi’s present address is: Italian Institute of Technology, Neuroscience and Brain Technologies Department, Genoa, Italy.


1. Bernstein M, et al. Ewing’s sarcoma family of tumors: current management. Oncologist. 2006;11(5):503–519. [PubMed]
2. Henderson DW, Leppard PJ, Brennan JS, Mukherjee TM, Swift JG. Primitive neuroepithelial tumours of soft tissues and of bone: further ultrastructural and immunocytochemical clarification of ‘Ewing’s sarcoma’, including freeze-fracture analysis. J Submicrosc Cytol Pathol. 1989;21(1):35–57. [PubMed]
3. Lipinski M, et al. Neuroectoderm-associated antigens on Ewing’s sarcoma cell lines. Cancer Res. 1987;47(1):183–187. [PubMed]
4. Lizard-Nacol S, Lizard G, Justrabo E, Turc-Carel C. Immunologic characterization of Ewing’s sarcoma using mesenchymal and neural markers. Am J Pathol. 1989;135(5):847–855. [PubMed]
5. Lizard-Nacol S, Volk C, Lizard G, Turc-Carel C. Abnormal expression of neurofilament proteins in Ewing’s sarcoma cell cultures. Tumour Biol. 1992;13(1–2):36–43. [PubMed]
6. Ladanyl M, Heinemann FS, Huvos AG, Rao PH, Chen QG, Jhanwar SC. Neural differentiation in small round cell tumors of bone and soft tissue with the translocation t(11;22)(q24;q12): an immunohistochemical study of 11 cases. Hum Pathol. 1990;21(12):1245–1251. doi: 10.1016/S0046-8177(06)80038-9. [PubMed] [Cross Ref]
7. Riggi N, et al. EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008;68(7):2176–2185. [PubMed]
8. Miyagawa Y, et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing’s family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol. 2008;28(7):2125–2137. doi: 10.1128/MCB.00740-07. [PMC free article] [PubMed] [Cross Ref]
9. Riggi N, et al. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005;65(24):11459–11468. doi: 10.1158/0008-5472.CAN-05-1696. [PubMed] [Cross Ref]
10. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11(5):421–429. doi: 10.1016/j.ccr.2007.02.027. [PubMed] [Cross Ref]
11. Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res. 2003;63(13):3464–3468. [PubMed]
12. Delattre O, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–165. doi: 10.1038/359162a0. [PubMed] [Cross Ref]
13. Barr FG, Womer RB. Molecular diagnosis of ewing family tumors: too many fusions...? J Mol Diagn. 2007;9(4):437–440. [PubMed]
14. May WA, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A. 1993;90(12):5752–5756. [PubMed]
15. May WA, et al. The Ewing’s sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13(12):7393–7398. [PMC free article] [PubMed]
16. Kovar H. Context matters: the hen or egg problem in Ewing’s sarcoma. Semin Cancer Biol. 2005;15(3):189–196. [PubMed]
17. Smith R, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell. 2006;9(5):405–416. doi: 10.1016/j.ccr.2006.04.004. [PubMed] [Cross Ref]
18. Lessnick SL, Dacwag CS, Golub TR. The Ewing’s sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 2002;1(4):393–401. doi: 10.1016/S1535-6108(02)00056-9. [PubMed] [Cross Ref]
19. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene. 2001;20(46):6731–6741. doi: 10.1038/sj.onc.1204875. [PubMed] [Cross Ref]
20. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res. 2005;65(11):4633–4644. [PubMed]
21. Rorie CJ, Thomas VD, Chen P, Pierce HH, O’Bryan JP, Weissman BE. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004;64(4):1266–1277. doi: 10.1158/0008-5472.CAN-03-3274. [PubMed] [Cross Ref]
22. Teitell MA, Thompson AD, Sorensen PH, Shimada H, Triche TJ, Denny CT. EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts. Lab Invest. 1999;79(12):1535–1543. [PubMed]
23. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272(49):30822–30827. doi: 10.1074/jbc.272.49.30822. [PubMed] [Cross Ref]
24. Kovar H, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing’s sarcoma and peripheral primitive neuroectodermal tumor. Oncogene. 1990;5(7):1067–1070. [PubMed]
25. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol. 2002;3(2):143–150. doi: 10.1038/ni749. [PubMed] [Cross Ref]
26. Schenkel AR, Dufour EM, Chew TW, Sorg E, Muller WA. The murine CD99-related molecule CD99-like 2 (CD99L2) is an adhesion molecule involved in the inflammatory response. Cell Commun Adhes. 2007;14(5):227–237. [PubMed]
27. Cerisano V, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing’s sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene. 2004;23(33):5664–5674. doi: 10.1038/sj.onc.1207741. [PubMed] [Cross Ref]
28. Bernard G, Zoccola D, Deckert M, Breittmayer JP, Aussel C, Bernard A. The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes. J Immunol. 1995;154(1):26–32. [PubMed]
29. Bernard G, et al. CD99 (E2) up-regulates alpha4beta1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol. 2000;30(10):3061–3065. doi: 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M. [PubMed] [Cross Ref]
30. Bernard G, et al. Apoptosis of immature thymocytes mediated by E2/CD99. . J Immunol. 1997;158(6):2543–2550. [PubMed]
31. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1991;67(7):1886–1893. doi: 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U. [PubMed] [Cross Ref]
32. Brown RE, Boyle JL. Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci. 2003;33(2):131–141. [PubMed]
33. Dworzak MN, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18(4):703–708. [PubMed]
34. Fellinger EJ, Garin-Chesa P, Triche TJ, Huvos AG, Rettig WJ. Immunohistochemical analysis of Ewing’s sarcoma cell surface antigen p30/32MIC2. Am J Pathol. 1991;139(2):317–325. [PubMed]
35. Kim SH, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin’s and Reed-Sternberg phenotype. Blood. 2000;95(1):294–300. [PubMed]
36. Manara MC, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell. 2006;17(4):1910–1921. doi: 10.1091/mbc.E05-10-0971. [PMC free article] [PubMed] [Cross Ref]
37. Ramani P, Rampling D, Link M. Immuno­cyto­chemical study of 12E7 in small round-cell tumours of childhood: an assessment of its sensitivity and specificity. Histopathology. 1993;23(6):557–561. doi: 10.1111/j.1365-2559.1993.tb01243.x. [PubMed] [Cross Ref]
38. Scotlandi K, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene. 2007;26(46):6604–6618. doi: 10.1038/sj.onc.1210481. [PubMed] [Cross Ref]
39. Scotlandi K, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing’s sarcoma. Eur J Cancer. 2006;42(1):91–96. doi: 10.1016/j.ejca.2005.09.015. [PubMed] [Cross Ref]
40. Scotlandi K, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res. 2000;60(18):5134–5142. [PubMed]
41. Steinman RA. Cell cycle regulators and hemato­poiesis. Oncogene. 2002;21(21):3403–3413. doi: 10.1038/sj.onc.1205325. [PubMed] [Cross Ref]
42. Matsumoto E, Hatanaka M, Bohgaki M, Maeda S. PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells. Kobe J Med Sci. 2006;52(6):181–194. [PubMed]
43. Matsunobu T, et al. The prognostic and therapeutic relevance of p27kip1 in Ewing’s family tumors. Clin Cancer Res. 2004;10(3):1003–1012. doi: 10.1158/1078-0432.CCR-0788-3. [PubMed] [Cross Ref]
44. Nakatani F, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem. 2003;278(17):15105–15115. doi: 10.1074/jbc.M211470200. [PubMed] [Cross Ref]
45. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2(4):339–345. [PubMed]
46. Trojanowski JQ, Walkenstein N, Lee VM. Expression of neurofilament subunits in neurons of the central and peripheral nervous system: an immuno­histochemical study with monoclonal antibodies. J Neurosci. 1986;6(3):650–660. [PubMed]
47. Casini T, Pelicci PG. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene. 1999;18(21):3235–3243. doi: 10.1038/sj.onc.1202630. [PubMed] [Cross Ref]
48. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25(11):2739–2749. doi: 10.1634/stemcells.2007-0197. [PubMed] [Cross Ref]
49. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147. [PubMed]
50. Smith JR, Pochampally R, Perry A, Hsu SC, Prockop DJ. Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. Stem Cells. 2004;22(5):823–831. doi: 10.1634/stemcells.22-5-823. [PubMed] [Cross Ref]
51. Blondheim NR, et al. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev. 2006;15(2):141–164. doi: 10.1089/scd.2006.15.141. [PubMed] [Cross Ref]
52. Tropel P, et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells. 2006;24(12):2868–2876. doi: 10.1634/stemcells.2005-0636. [PubMed] [Cross Ref]
53. Gonzalez I, Vicent S, de Alava E, Lecanda F. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med. 2007;85(9):1015–1029. doi: 10.1007/s00109-007-0202-5. [PubMed] [Cross Ref]
54. Kovar H, Bernard A. CD99-positive “Ewing’s sarcoma” from mouse-bone marrow-derived mesenchymal progenitor cells? Cancer Res. 2006. 66199786 ; author reply 9786 [PubMed]
55. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci. 2000;57(11):1613–1636. doi: 10.1007/PL00000645. [PubMed] [Cross Ref]
56. Yang H, Xia Y, Lu SQ, Soong TW, Feng ZW. Basic fibroblast growth factor-induced neuronal differentiation of mouse bone marrow stromal cells requires FGFR-1, MAPK/ERK, and transcription factor AP-1. J Biol Chem. 2008;283(9):5287–5295. doi: 10.1074/jbc.M706917200. [PubMed] [Cross Ref]
57. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol. 2004;14(3):311–317. doi: 10.1016/j.conb.2004.04.001. [PubMed] [Cross Ref]
58. Subramaniam S, Unsicker K. Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience. 2006;138(4):1055–1065. doi: 10.1016/j.neuroscience.2005.12.013. [PubMed] [Cross Ref]
59. Grewal SS, York RD, Stork PJ. Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol. 1999;9(5):544–553. doi: 10.1016/S0959-4388(99)00010-0. [PubMed] [Cross Ref]
60. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J. 1992;288(pt 2):351–355. [PubMed]
61. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing’s sarcoma. Mol Cancer Res. 2006;4(11):851–859. [PubMed]
62. Suva ML, et al. Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 2009;69(5):1776–1781. doi: 10.1158/0008-5472.CAN-08-2242. [PubMed] [Cross Ref]
63. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24(16):7275–7283. doi: 10.1128/MCB.24.16.7275-7283.2004. [PMC free article] [PubMed] [Cross Ref]
64. Hahn MJ, Yoon SS, Sohn HW, Song HG, Park SH, Kim TJ. Differential activation of MAP kinase family members triggered by CD99 engagement. FEBS Lett. 2000;470(3):350–354. doi: 10.1016/S0014-5793(00)01330-2. [PubMed] [Cross Ref]
65. Byun HJ, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem. 2006;281(46):34833–34847. doi: 10.1074/jbc.M605483200. [PubMed] [Cross Ref]
66. Fukunaga K, Miyamoto E. Role of MAP kinase in neurons. Mol Neurobiol. 1998;16(1):79–95. doi: 10.1007/BF02740604. [PubMed] [Cross Ref]
67. Silvany RE, Eliazer S, Wolff NC, Ilaria RL., Jr Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene. 2000;19(39):4523–4530. doi: 10.1038/sj.onc.1203811. [PubMed] [Cross Ref]
68. Diolaiti D, et al. Functional cooperation between TrkA and p75(NTR) accelerates neuronal differentiation by increased transcription of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 activities. Exp Cell Res. 2007;313(14):2980–2992. doi: 10.1016/j.yexcr.2007.06.002. [PubMed] [Cross Ref]
69. Lavaur J, et al. A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J Neurosci. 2007;27(52):14448–14458. doi: 10.1523/JNEUROSCI.2279-07.2007. [PubMed] [Cross Ref]
70. Perbal B, et al. Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res. 2008;14(3):701–709. doi: 10.1158/1078-0432.CCR-07-0806. [PubMed] [Cross Ref]
71. Munoz-Elias G, Woodbury D, Black IB. Marrow stromal cells, mitosis, and neuronal differentiation: stem cell and precursor functions. Stem Cells. 2003;21(4):437–448. doi: 10.1634/stemcells.21-4-437. [PubMed] [Cross Ref]
72. Zupanska A, Adach A, Dziembowska M, Kaminska B. Alternative pathway of transcriptional induction of p21WAF1/Cip1 by cyclosporine A in p53-deficient human glioblastoma cells. Cell Signal. 2007;19(6):1268–1278. doi: 10.1016/j.cellsig.2007.01.011. [PubMed] [Cross Ref]
73. Herrero-Martin D, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer. 2009;101(1):80–90. doi: 10.1038/sj.bjc.6605104. [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation